ADVERSE O
REACTIONS O
TOBI O
was O
generally O
well O
tolerated O
during O
two O
clinical O
studies O
in O
258 O
cystic B-Not_AE_Candidate
fibrosis I-Not_AE_Candidate
patients O
ranging O
in O
age O
from O
6 O
to O
48 O
years O
. O

Patients O
received O
TOBI O
in O
alternating O
periods O
of O
28 O
days O
on O
and O
28 O
days O
off O
drug O
in O
addition O
to O
their O
standard O
cystic B-Not_AE_Candidate
fibrosis I-Not_AE_Candidate
therapy O
for O
a O
total O
of O
24 O
weeks O
. O

Voice B-OSE_Labeled_AE
alteration I-OSE_Labeled_AE
and O
tinnitus B-OSE_Labeled_AE
were O
the O
only O
adverse O
experiences O
reported O
by O
significantly O
more O
TOBI-treated O
patients O
. O

Thirty-three O
patients O
( O
13 O
% O
) O
treated O
with O
TOBI O
complained O
of O
voice B-OSE_Labeled_AE
alteration I-OSE_Labeled_AE
compared O
to O
17 O
( O
7 O
% O
) O
placebo O
patients O
. O

Voice B-OSE_Labeled_AE
alteration I-OSE_Labeled_AE
was O
more O
common O
in O
the O
on-drug O
periods O
. O

Eight O
patients O
from O
the O
TOBI O
group O
( O
3 O
% O
) O
reported O
tinnitus B-OSE_Labeled_AE
compared O
to O
no O
placebo O
patients O
. O

All O
episodes O
were O
transient O
, O
resolved O
without O
discontinuation O
of O
the O
TOBI O
treatment O
regimen O
, O
and O
were O
not O
associated O
with O
loss B-NonOSE_AE
of I-NonOSE_AE
hearing I-NonOSE_AE
in O
audiograms O
. O

Tinnitus B-NonOSE_AE
is O
one O
of O
the O
sentinel O
symptoms O
of O
cochlear B-NonOSE_AE
toxicity I-NonOSE_AE
, O
and O
patients O
with O
this O
symptom O
should O
be O
carefully O
monitored O
for O
high O
frequency O
hearing B-NonOSE_AE
loss I-NonOSE_AE
. O

The O
numbers O
of O
patients O
reporting O
vestibular B-NonOSE_AE
adverse I-NonOSE_AE
experiences I-NonOSE_AE
such O
as O
dizziness B-NonOSE_AE
were O
similar O
in O
the O
TOBI O
and O
placebo O
groups O
. O

Nine O
( O
3 O
% O
) O
patients O
in O
the O
TOBI O
group O
and O
nine O
( O
3 O
% O
) O
patients O
in O
the O
placebo O
group O
had O
increases B-NonOSE_AE
in I-NonOSE_AE
serum I-NonOSE_AE
creatinine I-NonOSE_AE
of O
at O
least O
50 O
% O
over O
baseline O
. O

In O
all O
nine O
patients O
in O
the O
TOBI O
group O
, O
creatinine B-NonOSE_AE
decreased I-NonOSE_AE
at O
the O
next O
visit O
. O

Table O
1 O
lists O
the O
percent O
of O
patients O
with O
treatment-emergent O
adverse O
experiences O
( O
spontaneously O
reported O
and O
solicited O
) O
that O
occurred O
in O
> O
5 O
% O
of O
TOBI O
patients O
during O
the O
two O
Phase O
III O
studies O
. O

Table O
1 O
: O
Percent O
of O
Patients O
With O
Treatment O
Emergent O
Adverse O
Experiences O
Occurring O
in O
> O
5 O
% O
of O
TOBI O
Patients O
1 O
Includes O
subjective O
complaints O
of O
fever B-NonOSE_AE
. O

2 O
Includes O
reported O
decreases B-OSE_Labeled_AE
in I-OSE_Labeled_AE
pulmonary I-OSE_Labeled_AE
function I-OSE_Labeled_AE
tests I-OSE_Labeled_AE
or O
decreased B-OSE_Labeled_AE
lung I-OSE_Labeled_AE
volume I-OSE_Labeled_AE
on I-OSE_Labeled_AE
chest I-OSE_Labeled_AE
radiograph I-OSE_Labeled_AE
associated O
with O
intercurrent O
illness O
or O
study O
drug O
administration O
. O

Adverse O
Event O
TOBI O
( O
n=258 O
) O
% O
Placebo O
( O
n=262 O
) O
% O
Cough B-NonOSE_AE
Increased I-NonOSE_AE
46.1 O
47.3 O
Pharyngitis B-NonOSE_AE
38.0 O
39.3 O
Sputum B-NonOSE_AE
Increased I-NonOSE_AE
37.6 O
39.7 O
Asthenia B-NonOSE_AE
35.7 O
39.3 O
Rhinitis B-OSE_Labeled_AE
34.5 O
33.6 O
Dyspnea B-NonOSE_AE
33.7 O
38.5 O
Fever B-NonOSE_AE
1 O
32.9 O
43.5 O
Lung B-OSE_Labeled_AE
Disorder I-OSE_Labeled_AE
31.4 O
31.3 O
Headache B-NonOSE_AE
26.7 O
32.1 O
Chest B-NonOSE_AE
Pain I-NonOSE_AE
26.0 O
29.8 O
Sputum B-OSE_Labeled_AE
Discoloration I-OSE_Labeled_AE
21.3 O
19.8 O
Hemoptysis B-NonOSE_AE
19.4 O
23.7 O
Anorexia B-NonOSE_AE
18.6 O
27.9 O
Lung B-OSE_Labeled_AE
Function I-OSE_Labeled_AE
Decreased I-OSE_Labeled_AE
2 O
16.3 O
15.3 O
Asthma B-NonOSE_AE
15.9 O
20.2 O
Vomiting B-NonOSE_AE
14.0 O
22.1 O
Abdominal B-NonOSE_AE
Pain I-NonOSE_AE
12.8 O
23.7 O
Voice B-OSE_Labeled_AE
Alteration I-OSE_Labeled_AE
12.8 O
6.5 O
Nausea B-NonOSE_AE
11.2 O
16.0 O
Weight B-NonOSE_AE
Loss I-NonOSE_AE
10.1 O
15.3 O
Pain B-NonOSE_AE
8.1 O
12.6 O
Sinusitis B-NonOSE_AE
8.1 O
9.2 O
Ear B-NonOSE_AE
Pain I-NonOSE_AE
7.4 O
8.8 O
Back B-NonOSE_AE
Pain I-NonOSE_AE
7.0 O
8.0 O
Epistaxis B-OSE_Labeled_AE
7.0 O
6.5 O
Taste B-NonOSE_AE
Perversion I-NonOSE_AE
6.6 O
6.9 O
Diarrhea B-NonOSE_AE
6.2 O
10.3 O
Malaise B-OSE_Labeled_AE
6.2 O
5.3 O
Lower B-NonOSE_AE
Respiratory I-NonOSE_AE
Tract I-NonOSE_AE
Infection I-NonOSE_AE
5.8 O
8.0 O
Dizziness B-NonOSE_AE
5.8 O
7.6 O
Hyperventilation B-NonOSE_AE
5.4 O
9.9 O
Rash B-NonOSE_AE
5.4 O
6.1 O
Adverse O
drug O
reactions O
( O
< O
5 O
% O
) O
occurring O
more O
frequently O
with O
TOBI O
in O
the O
placebo-controlled O
studies O
and O
assessed O
as O
drug-related O
in O
> O
=1 O
% O
of O
patients O
: O
Ear B-NonOSE_AE
and I-NonOSE_AE
labyrinth I-NonOSE_AE
disorders I-NonOSE_AE
Tinnitus B-OSE_Labeled_AE
( O
3.1 O
% O
, O
vs O
0 O
% O
for O
placebo O
) O
Musculoskeletal B-NonOSE_AE
and I-NonOSE_AE
connective I-NonOSE_AE
tissue I-NonOSE_AE
disorders I-NonOSE_AE
Myalgia B-OSE_Labeled_AE
( O
4.7 O
% O
, O
vs O
2.7 O
% O
for O
placebo O
) O
Infections B-NonOSE_AE
and I-NonOSE_AE
infestations I-NonOSE_AE
Laryngitis B-OSE_Labeled_AE
( O
4.3 O
% O
, O
vs O
3.1 O
% O
for O
placebo O
) O
Adverse O
drug O
reactions O
derived O
from O
spontaneous O
reports O
The O
following O
adverse O
reactions O
have O
been O
identified O
during O
postapproval O
use O
of O
TOBI O
. O

Because O
these O
reactions O
are O
reported O
voluntarily O
from O
a O
population O
of O
uncertain O
size O
, O
it O
is O
not O
always O
possible O
to O
reliably O
estimate O
their O
frequency O
or O
establish O
a O
causal O
relationship O
to O
drug O
exposure O
. O

Ear B-NonOSE_AE
and I-NonOSE_AE
labyrinth I-NonOSE_AE
disorders I-NonOSE_AE
Hearing B-OSE_Labeled_AE
loss I-OSE_Labeled_AE
( O
see O
WARNINGS O
- O
Ototoxicity O
) O
Skin B-NonOSE_AE
and I-NonOSE_AE
subcutaneous I-NonOSE_AE
tissue I-NonOSE_AE
disorders I-NonOSE_AE
Hypersensitivity B-OSE_Labeled_AE
, O
pruritus B-OSE_Labeled_AE
, O
urticaria B-OSE_Labeled_AE
, O
rash B-OSE_Labeled_AE
Nervous B-NonOSE_AE
system I-NonOSE_AE
disorders I-NonOSE_AE
Aphonia B-OSE_Labeled_AE
, O
dysgeusia B-OSE_Labeled_AE
Respiratory B-NonOSE_AE
, I-NonOSE_AE
thoracic I-NonOSE_AE
, I-NonOSE_AE
and I-NonOSE_AE
mediastinal I-NonOSE_AE
disorders I-NonOSE_AE
Bronchospasm B-OSE_Labeled_AE
( O
see O
WARNINGS O
- O
Bronchospasm B-OSE_Labeled_AE
) O
, O
oropharyngeal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
Metabolism B-NonOSE_AE
and I-NonOSE_AE
Nutrition I-NonOSE_AE
Disorders I-NonOSE_AE
Decreased B-OSE_Labeled_AE
appetite I-OSE_Labeled_AE

